NCT05723653 Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention
| NCT ID | NCT05723653 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | HIV Seropositivity |
| Study Type | INTERVENTIONAL |
| Enrollment | 900 participants |
| Start Date | 2023-02-13 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 900 participants in total. It began in 2023-02-13 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this Hybrid Type I effectiveness-implementation trial is to test an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV aged 18-49.
Eligibility Criteria
Inclusion Criteria for Index Participants: * Aged 18-49 years old, inclusive * Speak English * Own a cell phone not shared with anyone else * Have missed at least one HIV care scheduled visit or have not been virally suppressed in the past 24 months. * Resides in Chicagoland, Illinois or Alabama Exclusion Criteria for Index Men: * If a participant fails to meet all inclusion criteria Inclusion Criteria for Support Confidants: * Index agrees to engage the Support Confidant * Age 18 years or older * Speaks English * Owns a cell phone not shared with others * Is not a romantic/sexual partner of the Index participant Exclusion Criteria: * Romantic/Sexual partners of Index participant * Relationship strain or abuse present in Index-Support Confidant relationship
Contact & Investigator
Alida Bouris, PhD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT05723653 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 49 Years, studying HIV Seropositivity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05723653 currently recruiting?
Yes, NCT05723653 is actively recruiting participants. Contact the research team at abouris@uchicago.edu for enrollment information.
Where is the NCT05723653 trial being conducted?
This trial is being conducted at Birmingham, United States, Birmingham, United States, Huntsville, United States, Chicago, United States and 3 additional locations.
Who is sponsoring the NCT05723653 clinical trial?
NCT05723653 is sponsored by University of Chicago. The principal investigator is Alida Bouris, PhD at University of Chicago. The trial plans to enroll 900 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.